0 Commentaires
0 Parts
1KB Vue
0 Aperçu
Rechercher
Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis
-
Fil d’actualités
- EXPLORER
-
Pages
-
Groupes
-
Evènements
-
Reels
-
Blogs
-
Offres
-
Emplois
-
Connectez-vous pour aimer, partager et commenter!
-
Advancing Biologic Therapies: Targeted Monoclonal Antibodies in the IgG4-Related Disease MarketThe landscape of rare autoimmune management is shifting toward precision medicine. In the current medical environment, the focus on specific technologies like monoclonal antibody infusions has revolutionized how clinicians approach fibro-inflammatory conditions. These biologics are designed to target B-cell populations, offering a more refined approach compared to traditional broad-spectrum...0 Commentaires 0 Parts 1KB Vue 0 Aperçu
-
CD44 Antibody Market: Why Are Monoclonal Antibodies the Dominant Product Segment?CD44 monoclonal antibody — the in vitro-generated anti-CD44 antibodies with defined specificity and reproducibility representing the dominant product segment in research reagents — creates the most commercially consistent market segment, with the CD44 Antibody Market reflecting monoclonal antibodies as the premium quality driver. The market is projecting 10.8% CAGR from...0 Commentaires 0 Parts 10 Vue 0 Aperçu
-
Are Immune-Modulating Biologics Redefining the Future of Cancer Immunotherapy?Executive Summary Immune-Modulating Oncology Biologic Drugs Market Size and Share: Global Industry Snapshot CAGR Value The global immune-modulating oncology biologic drugs market size was valued at USD 10.10 billion in 2025 and is expected to reach USD 28.54 billion by 2033, at a CAGR of13.87% during the forecast period The research and analysis...0 Commentaires 0 Parts 1KB Vue 0 Aperçu